Journey Medical Corporation DERM
4.44 USD +0.02 (+0.45%)
At closeNov 11, 2026, 4:00 PM EST
4.44 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
4.39 Day range 4.56
4.25 52-week range 9.56
- YTD
- -42.41%
- 1 year
- -50.94%
News
globenewswire.com Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
defenseworld.net Vireo Growth (OTCMKTS:VREOD) vs. Journey Medical (NASDAQ:DERM) Critical Contrast Journey Medical (NASDAQ: DERM - Get Free Report) and Vireo Growth (OTCMKTS:VREOD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the…
seekingalpha.com Journey Medical: A Small Pharma With A Large Growth Opportunity Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and…
globenewswire.com Journey Medical Corporation to Participate in September 2026 Investor Conferences SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and…
zacks.com ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
seekingalpha.com Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with…
benzinga.com B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15 B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…
seekingalpha.com Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
zacks.com Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
benzinga.com Journey Medical Q2 EPS $(0.01) Beats $(0.02) Estimate, Sales $17.839M Miss $18.366M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of…
globenewswire.com Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on…
globenewswire.com Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on…
seekingalpha.com Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
zacks.com Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
benzinga.com Transcript: Journey Medical Q1 2026 Earnings Conference Call 
benzinga.com Journey Medical Q1 EPS $(0.08), Inline, Sales $15.961M Beat $15.948M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same…
globenewswire.com Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position…
benzinga.com Earnings Scheduled For May 13, 2026 
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are…
globenewswire.com Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a…
zacks.com Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation (“Journey” or the “Company”) (NASDAQ: DERM). Such investors…
globenewswire.com Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
benzinga.com Journey Medical Q4 EPS $(0.04) Beats $(0.06) Estimate, Sales $16.079M Miss $18.863M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 31.03 percent. This is a 150 percent decrease over earnings of…- benzinga.com Earnings Scheduled For March 25, 2026
benzinga.com Journey Medical Files $3.75M At-The-Market Common Stock Offering With B. Riley And Lake Street 3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc. ("B. Riley") and Lake Street Capital Markets, LLC…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Journey Medical Q3 EPS $(0.09) Misses $(0.04) Estimate, Sales $17.631M Miss $18.854M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 143.24 percent. This is a 25 percent increase over losses of…- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Insights into Journey Medical's Upcoming Earnings - benzinga.com Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Lake Street Maintains Buy on Journey Medical, Raises Price Target to $13 Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $13.
benzinga.com CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Journey Medical Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $15.009M Beat $14.933M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 5.88 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Examining the Future: Journey Medical's Earnings Outlook
benzinga.com B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12 B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.- benzinga.com Journey Medical's Emrosi Now Covered For 65% Of U.S. Commercial Lives, Up From 29% In May Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to…
- benzinga.com Journey Medical To Join Russell 2000 And Russell 3000 Indexes, Effective After The Close Of U.S. Equity Markets On June 27, 2025 Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session